{
    "organizations": [],
    "uuid": "3cefbf942ca95a4d906b4422912e518298d0a3e2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nanobiotix-fy-revenue-down-at-03-m/brief-nanobiotix-fy-revenue-down-at-0-3-million-euros-idUSFWN1QI1GK",
    "ord_in_thread": 0,
    "title": "BRIEF-Nanobiotix FY Revenue Down At ‍​0.3 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - NANOBIOTIX SA:\n* FY REVENUE EUR ‍​0.3 MILLION VERSUS EUR 1.6 MILLION YEAR AGO\n* TO PRESENT RESULTS OF SOFT TISSUE SARCOMA PHASE II/III TRIAL WITH NBTXR3 IN Q2 2018‍​\n* TO START IN Q2 2018 PHASE I/II CLINICAL TRIAL OF NBTXR3 ACTIVATED BY RADIOTHERAPY WITH ANTI-PD1 ANTIBODY IN CANCER PATIENTS‍​ Source text: bit.ly/2t1m1Gt Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-01T01:47:00.000+02:00",
    "crawled": "2018-03-01T21:39:17.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "nanobiotix",
        "sa",
        "fy",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "present",
        "result",
        "soft",
        "tissue",
        "sarcoma",
        "phase",
        "trial",
        "nbtxr3",
        "q2",
        "start",
        "q2",
        "phase",
        "clinical",
        "trial",
        "nbtxr3",
        "activated",
        "radiotherapy",
        "antibody",
        "cancer",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}